Literature DB >> 17869217

Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells.

Biju Parekkadan1, Daan van Poll, Zaki Megeed, Naoya Kobayashi, Arno W Tilles, François Berthiaume, Martin L Yarmush.   

Abstract

Bone marrow-derived mesenchymal stem cells (MSCs) have been reported to prevent the development of liver fibrosis in a number of pre-clinical studies. Marked changes in liver histopathology and serological markers of liver function have been observed without a clear understanding of the therapeutic mechanism by which stem cells act. We sought to determine if MSCs could modulate the activity of resident liver cells, specifically hepatic stellate cells (SCs) by paracrine mechanisms using indirect cocultures. Indirect coculture of MSCs and activated SCs led to a significant decrease in collagen deposition and proliferation, while inducing apoptosis of activated SCs. The molecular mechanisms underlying the modulation of SC activity by MSCs were examined. IL-6 secretion from activated SCs induced IL-10 secretion from MSCs, suggesting a dynamic response of MSCs to the SCs in the microenvironment. Blockade of MSC-derived IL-10 and TNF-alpha abolished the inhibitory effects of MSCs on SC proliferation and collagen synthesis. In addition, release of HGF by MSCs was responsible for the marked induction of apoptosis in SCs as determined by antibody-neutralization studies. These findings demonstrate that MSCs can modulate the function of activated SCs via paracrine mechanisms provide a plausible explanation for the protective role of MSCs in liver inflammation and fibrosis, which may also be relevant to other models of tissue fibrosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17869217      PMCID: PMC2096777          DOI: 10.1016/j.bbrc.2007.05.150

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  24 in total

Review 1.  Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury.

Authors:  S L Friedman
Journal:  J Biol Chem       Date:  2000-01-28       Impact factor: 5.157

2.  Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation.

Authors:  Gary R Grotendorst; Hamed Rahmanie; Matthew R Duncan
Journal:  FASEB J       Date:  2004-03       Impact factor: 5.191

3.  Matrix-mediated retention of adipogenic differentiation potential by human adult bone marrow-derived mesenchymal stem cells during ex vivo expansion.

Authors:  Joshua R Mauney; Vladimir Volloch; David L Kaplan
Journal:  Biomaterials       Date:  2005-11       Impact factor: 12.479

4.  Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis.

Authors:  Tatiana Kisseleva; Hiroshi Uchinami; Nikki Feirt; Oscar Quintana-Bustamante; Jose Carlos Segovia; Robert F Schwabe; David A Brenner
Journal:  J Hepatol       Date:  2006-06-09       Impact factor: 25.083

5.  The bone marrow functionally contributes to liver fibrosis.

Authors:  Francesco P Russo; Malcolm R Alison; Brian W Bigger; Eunice Amofah; Aikaterini Florou; Farhana Amin; George Bou-Gharios; Rosemary Jeffery; John P Iredale; Stuart J Forbes
Journal:  Gastroenterology       Date:  2006-05       Impact factor: 22.682

6.  Bone marrow-derived mesenchymal stem cells protect against experimental liver fibrosis in rats.

Authors:  Dong-Chang Zhao; Jun-Xia Lei; Rui Chen; Wei-Hua Yu; Xiu-Ming Zhang; Shu-Nong Li; Peng Xiang
Journal:  World J Gastroenterol       Date:  2005-06-14       Impact factor: 5.742

7.  Rat liver myofibroblasts and hepatic stellate cells differ in CD95-mediated apoptosis and response to TNF-alpha.

Authors:  Bernhard Saile; Nina Matthes; Katrin Neubauer; Christoph Eisenbach; Hammoudeh El-Armouche; Joszef Dudas; Giuliano Ramadori
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-08       Impact factor: 4.052

8.  Establishment of an immortalized human hepatic stellate cell line to develop antifibrotic therapies.

Authors:  Norikuni Shibata; Takamasa Watanabe; Teru Okitsu; Masakiyo Sakaguchi; Michihiko Takesue; Takemi Kunieda; Kenji Omoto; Shinichiro Yamamoto; Noriaki Tanaka; Naoya Kobayashi
Journal:  Cell Transplant       Date:  2003       Impact factor: 4.064

9.  Caspase 9-dependent killing of hepatic stellate cells by activated Kupffer cells.

Authors:  Richard Fischer; Alexandra Cariers; Roland Reinehr; Dieter Häussinger
Journal:  Gastroenterology       Date:  2002-09       Impact factor: 22.682

10.  Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects.

Authors:  Luis A Ortiz; Frederica Gambelli; Christine McBride; Dina Gaupp; Melody Baddoo; Naftali Kaminski; Donald G Phinney
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-18       Impact factor: 12.779

View more
  83 in total

1.  GD2 expression is closely associated with neuronal differentiation of human umbilical cord blood-derived mesenchymal stem cells.

Authors:  Hye Jin Jin; Hae Yun Nam; Yun Kyong Bae; Soo Yeon Kim; I Rang Im; Wonil Oh; Yoon Sun Yang; Soo Jin Choi; Seong Who Kim
Journal:  Cell Mol Life Sci       Date:  2010-02-18       Impact factor: 9.261

Review 2.  Liver progenitor cells-mediated liver regeneration in liver cirrhosis.

Authors:  Haitao Shang; Zhijun Wang; Yuhu Song
Journal:  Hepatol Int       Date:  2016-01-07       Impact factor: 6.047

Review 3.  Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies.

Authors:  Jing-Ting Li; Zhang-Xiu Liao; Jie Ping; Dan Xu; Hui Wang
Journal:  J Gastroenterol       Date:  2008-07-04       Impact factor: 7.527

Review 4.  Mesenchymal stromal cells as supportive cells for hepatocytes.

Authors:  Alejandro Gómez-Aristizábal; Armand Keating; John E Davies
Journal:  Mol Ther       Date:  2009-07-07       Impact factor: 11.454

5.  Outcomes of autologous bone marrow mononuclear cell transplantation in decompensated liver cirrhosis.

Authors:  Yang-Qiu Bai; Yu-Xiu Yang; Ya-Ge Yang; Song-Ze Ding; Fang-Li Jin; Ming-Bo Cao; Yan-Rui Zhang; Bing-Yong Zhang
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 6.  Use of mesenchymal stem cells to treat liver fibrosis: current situation and future prospects.

Authors:  Silvia Berardis; Prenali Dwisthi Sattwika; Mustapha Najimi; Etienne Marc Sokal
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

Review 7.  Multipotent mesenchymal stromal cells: A promising strategy to manage alcoholic liver disease.

Authors:  Fernando Ezquer; Flavia Bruna; Sebastián Calligaris; Paulette Conget; Marcelo Ezquer
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

8.  Mesenchymal Stem Cells Overexpressing IFN-β Inhibit Breast Cancer Growth and Metastases through Stat3 Signaling in a Syngeneic Tumor Model.

Authors:  Xiaoyang Ling; Frank Marini; Marina Konopleva; Wendy Schober; Yuexi Shi; Jared Burks; Karen Clise-Dwyer; Rui-Yu Wang; Weiguo Zhang; Xiaoqing Yuan; Hongbo Lu; Lisa Caldwell; Michael Andreeff
Journal:  Cancer Microenviron       Date:  2010-03-19

Review 9.  Implications of the immunoregulatory functions of mesenchymal stem cells in the treatment of human liver diseases.

Authors:  Hu Lin; Ruonan Xu; Zheng Zhang; Liming Chen; Ming Shi; Fu-Sheng Wang
Journal:  Cell Mol Immunol       Date:  2010-11-22       Impact factor: 11.530

10.  Bone marrow-derived stromal cell therapy in cirrhosis: clinical evidence, cellular mechanisms, and implications for the treatment of hepatocellular carcinoma.

Authors:  Jeffrey M Vainshtein; Rafi Kabarriti; Keyur J Mehta; Jayanta Roy-Chowdhury; Chandan Guha
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-15       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.